Talaris Therapeutics Announces Upcoming Presentations at American Transplant Congress
02 mai 2022 07h00 HE
|
Talaris Therapeutics, Inc.
Data to be presented include real-world evidence analysis of health outcomes among Phase 2 patients compared to matched controlsUpdated data on Phase 2 study follow-up, COVID-19 patient outcomes also...
Talaris Therapeutics Presents Data on COVID-19 Outcomes Among Kidney Transplant Patients Treated with FCR001
06 avr. 2022 16h01 HE
|
Talaris Therapeutics, Inc.
Low rate of COVID-19 infection observed in vaccinated, durably chimeric patients off immunosuppression No evidence of acute kidney injury or impaired renal function in FCR001-treated patients with...
Talaris Therapeutics to Participate at Two Upcoming Investor Conferences
22 mars 2022 16h01 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., March 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Announces Fourth Quarter and Year-End Financial Results
17 mars 2022 16h01 HE
|
Talaris Therapeutics, Inc.
Phase 3 (FREEDOM-1) clinical trial in living donor kidney transplant (LDKT) patients continues; additional data update expected mid-year 2022 Two Phase 2 (FREEDOM-2 and FREEDOM-3) clinical trials...
Talaris Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
11 févr. 2022 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
06 janv. 2022 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
04 janv. 2022 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Announces Addition to the Nasdaq Biotechnology Index
20 déc. 2021 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Presents High-Resolution Analysis of HLA Mismatching in Phase 2 Trial in Living Donor Kidney Transplant
14 déc. 2021 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., (Nasdaq: TALS), a late-clinical stage cell therapy company, today presented a new analysis of HLA...
Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Individuals with a Severe Form of Scleroderma
30 nov. 2021 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...